Bristol-Myers Squibb’s blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.
Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.
The EMA’s risk assessment committee recommended restrictions on the use of the broad-spectrum antibiotics.
Immunotherapy – reprogramming the immune system to attack cancer cells – is a rapidly growing and promising field in cancer research and treatment.
Eli Lilly’s new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending the company’s shares to a record high and weighing on those of arch-rival Novo Nordisk.
Janssen Biotech informed Aduro Biotech that the Johnson & Johnson company was terminating a research and license deal related to Aduro’s Listeria treatment for cancers.
Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.
Eli Lilly signed a licensing deal for Chugai Pharmaceutical’s oral non-peptidic GLP-1 receptor agonist OWL833.
Johnson & Johnson and Geron had teamed up to develop and commercialize imetelstat, a first-in-class telomerase inhibitor, for myelofibrosis and myelodysplastic syndromes.
An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.
A Cuban-developed lung cancer treatment combined with Bristol-Myers Squibb’s anti-PDL1 Opdivo shows promise in treating patients who would not likely benefit from immune checkpoint inhibition.
Alexion Pharmaceuticals is acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn), for a total value of up to $1.2 billion.
AstraZeneca’s immunotherapy drug Imfinzi was approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.
In Amarin’s REDUCE-IT clinical trial of 8,179 statin-treated adults with increased risk of cardiovascular problems, the drug showed a 25 percent relative risk reduction in major adverse cardiovascular events compared to placebo.
Tokyo-based Astellas Pharma announced that the company’s roxadustat met the primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease patients with anemia not on dialysis.
Bayer AG’s long-acting treatment for hemophilia A won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily.
Shares of OncoMed Pharmaceuticals fell after the company announced that Celgene walked away from a deal to license the bispecific antibody navicixizumab.
AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.
Denmark-based Zealand Pharma announced that the company’s Phase III trial for dasiglucagon for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints, setting up potential regulatory approval.